Dose-dependency of adenosine on cell-surface expression of membrane molecules in iDCs
| iDC . | Treatment . | |||
|---|---|---|---|---|
| None . | 10−5 M adenosine . | 10−4 M adenosine . | 10−3 M adenosine . | |
| CD86 | 40.1 ± 4.6 | 51.7 ± 4.7 | 71.8 ± 4.6 | 73.6 ± 5.7 |
| CD80 | 32.8 ± 7.1 | 45.3 ± 8.7 | 64.0 ± 7.4 | 67.9 ± 6.2 |
| MHC I | 176.6 ± 48.3 | 223.4 ± 54.7 | 275.5 ± 33.6 | 288.6 ± 33.7 |
| HLA-DR | 171.6 ± 38.8 | 286.9 ± 38.9 | 529.8 ± 39.7 | 569.3 ± 61.5 |
| iDC . | Treatment . | |||
|---|---|---|---|---|
| None . | 10−5 M adenosine . | 10−4 M adenosine . | 10−3 M adenosine . | |
| CD86 | 40.1 ± 4.6 | 51.7 ± 4.7 | 71.8 ± 4.6 | 73.6 ± 5.7 |
| CD80 | 32.8 ± 7.1 | 45.3 ± 8.7 | 64.0 ± 7.4 | 67.9 ± 6.2 |
| MHC I | 176.6 ± 48.3 | 223.4 ± 54.7 | 275.5 ± 33.6 | 288.6 ± 33.7 |
| HLA-DR | 171.6 ± 38.8 | 286.9 ± 38.9 | 529.8 ± 39.7 | 569.3 ± 61.5 |
Immature DCs were stimulated with the indicated concentration of adenosine for 48 hours. The expression of the indicated molecules or isotype control was analyzed by flow cytometry. Data indicate the net MFI ± SEM (n = 3).